Lower risk of hospitalization for heart failure, kidney disease and death with sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care

Abstract

AimTo assess if sodium‐glucose co‐transporter‐2 inhibitors (SGLT2is) reduce the risk of all‐cause mortality, cardiovascular death and hospitalization for heart failure (HF) or chronic kidney disease (CKD) to a greater extent than dipeptidyl peptidase‐4 inhibitors (DPP4is) in people with type 2 diabetes (T2D) with or without established cardiovascular and/or renal disease (CVRD).MethodsThis retrospective cohort study propensity‐matched 24 438 patients receiving an SGLT2i 1:1 to a patient receiving a DDP4i, stratified based on the presence of CVRD. The primary outcomes were the time to each of the following: all‐cause mortality, cardiovascular death or hospitalization for HF, myocardial infarction, stroke and CKD.ResultsOverall, SGLT2is were associated with reductions in all‐cause mortality, cardiovascular mortality, hospitalization for HF and hospitalization for CKD compared with DPP4is. In patients with no CVRD history, SGLT2is were associated with reductions in all‐cause mortality (HR 0.71, 95% CI 0.57‐0.88; P = .002), hospitalization for HF (HR 0.76, 95% CI 0.59‐0.98; P = .035) and hospitalization for CKD (HR 0.75, 95% CI 0.63‐0.88; P < .001). In patients with established cardiovascular disease (CVD) or at high risk, SGLT2is were associated with reductions in all‐cause mortality (HR 0.69, 95% CI 0.59‐0.82; P < .001), cardiovascular mortality (HR 0.76, 95% CI 0.62‐0.95; P = .014), hospitalization for HF (HR 0.73, 95% CI 0.63‐0.85; P < .001), hospitalization for stroke (HR 0.75, 95% CI 0.59‐0.94; P = .013) and hospitalization for CKD (HR 0.49, 95% CI 0.43‐0.54; P < .001).ConclusionThere was consistency across subgroups and sensitivity analyses. SGLT2is were associated with a reduced risk of all‐cause mortality and hospitalization for HF and CKD compared with DPP4‐is, highlighting the need to introduce SGLT2is early in the management of patients with T2D.